Dr. Ogunniyi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Emory University School of Medicine, Div of Cardiology
49 Jesse Hill Jr Dr
Atlanta, GA 30303Phone+1 404-616-4440
Summary
- Board-certified Cardiologist and Professor of Medicine with an interest and research focus on examining social determinants of health and eliminating disparities in cardiovascular disease, specifically, hypertension and heart failure, palliative care in heart failure, diversity in clinical trials, and cardiovascular disease in women. As a cardiovascular epidemiologist, I seek to forge links between preventive medicine, public policy, quality improvement, and scientific research. Passionate about mentorship and diversifying the workforce in Medicine.
Education & Training
- Vanderbilt University Medical CenterFellowship, Cardiovascular Disease, 2006 - 2009
- Morehouse School of MedicineResidency, Internal Medicine, 2003 - 2006
- Centers for Disease Control and PreventionPost-Doctoral Fellowship, 2001 - 2002
- Johns Hopkins UniversityMPH, Public Health, 2000 - 2001
- University of IbadanClass of 1999
Certifications & Licensure
- GA State Medical License 2007 - 2025
- TN State Medical License 2006 - 2011
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- FAHA American Heart Association
- FACP American College of Physicians
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Start of enrollment: 2016 Mar 03
- Dapagliflozin in PRESERVED Ejection Fraction Heart Failure Start of enrollment: 2017 Mar 01
- Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure Start of enrollment: 2017 Feb 08
- Join now to see all
Publications & Presentations
PubMed
- 1858 citationsDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod
The New England Journal of Medicine. 2019-11-21 - 742 citationsDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.Scott D Solomon, John J V McMurray, Brian Claggett, Rudolf A de Boer, David DeMets
The New England Journal of Medicine. 2022-09-22 - 24 citationsEfficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of...Jawad H. Butt, Kieran F. Docherty, Mark C. Petrie, Morten Schou, Mikhail Kosiborod
JAMA Cardiology. 2021-06-01
Press Mentions
- Feature | Advancing Health Equity for Heart Failure Patients: A Case Study for Team-Based Care and InnovationOctober 15th, 2020
Professional Memberships
- Fellow
- Fellow
- Fellow
- Association of Black CardiologistsMember
- Member
- Member
- National Medical AssociationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: